News KALA BIO, Inc.

Equities

KALA

US4831192020

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
6.3 ^USD	+1.94%		-4.40%	-10.00%

Apr. 02	HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	MT
Mar. 29	KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	Apr. 02	MT
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Apr. 01	AQ
KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
KALA BIO, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Mar. 29	AQ
KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP	Mar. 24	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference	Feb. 26	AQ
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	AQ
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 19	AQ
KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding	Dec. 20	CI
HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $22 From $24, Maintains Buy Rating	Nov. 17	MT
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating	Nov. 14	MT
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 13	AQ
KALA BIO Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	23-09-21	AQ
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23-09-20	AQ
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference	23-09-05	AQ
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update	23-08-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News KALA BIO, Inc.

Equities

KALA

US4831192020

Summary

Filters